STOCKS TELEGRAPH

Tag: Exela stock

  • Is Exelixis Inc. (EXEL) Stock a Good Buy? Key Factors to Consider

    Is Exelixis Inc. (EXEL) Stock a Good Buy? Key Factors to Consider

    Exelixis Inc. (NASDAQ: EXEL) is a leading biotech company specializing in the discovery, development, and commercialization of cancer treatments. As the biotech sector experiences increased volatility and investor attention, Exelixis stock (EXEL) has become a focal point for traders and long-term investors alike. Given its strong pipeline of oncology treatments and steady revenue growth, many are questioning: Is EXEL stock a good buy today?

    Over the past year, EXEL stock performance has been influenced by drug approvals, clinical trial results, and broader market trends. Investors are keen to understand whether Exelixis stock forecast suggests a strong upside or if the risks outweigh the potential gains. With a robust R&D pipeline, solid financials, and competitive positioning in the biotech space, Exelixis presents an intriguing investment opportunity.

    So, should you buy EXEL stock today? This article will analyze key factors, including financial performance, growth drivers, risks, and expert opinions to help you decide.

    Exelixis (EXEL) Stock Overview

    Exelixis (EXEL) has shown moderate fluctuations in its recent trading session, reflecting both market sentiment and the biotech sector’s overall performance. The stock opened at $37.05 but saw intraday volatility, reaching a day low of $36.97 before rebounding to a day high of $37.64. It closed at $36.92, slightly lower than the previous close of $37.05, indicating a minor pullback.

    With a market capitalization of $10.5 billion, Exelixis remains a key player in the biotech industry, leveraging its innovative oncology pipeline for future growth. The company’s P/E ratio stands at 21.32, suggesting a reasonable valuation compared to industry peers. The earnings per share (EPS) is 1.76, reflecting strong profitability, while the book value per share is 7.34, providing insight into the company’s underlying financial strength.

    Trading volume for the session stood at 2 million shares, indicating steady investor interest in EXEL stock. The stock’s free float is 97.3%, meaning most of its shares are available for public trading, contributing to liquidity and price movement.

    With cash flow per share at $0.55, Exelixis continues to maintain a solid financial position, allowing for sustained research and development investments.

    Over the past 12 months, EXEL stock price has shown moderate volatility, influenced by earnings reports, FDA approvals, and biotech sector trends. The stock has traded between $17 and $25, reflecting shifts in investor sentiment. EXEL stock vs biotech stocks comparison reveals that while some competitors have struggled, Exelixis has maintained steady momentum.

    Financial Performance & Earnings Analysis

    Earnings and Revenue Growth

    A key aspect of EXEL stock analysis is evaluating its financial health. Exelixis has reported consistent revenue growth, with total revenue surpassing $1.5 billion in recent quarters, primarily driven by Cabometyx sales. Exelixis revenue growth has been fueled by strong demand for its cancer treatments and ongoing licensing agreements.

    Exelixis (EXEL) Income Statement Analysis

    Exelixis has demonstrated strong revenue growth and profitability over the past five quarters, showcasing its financial stability and operational efficiency. The latest Q3 2024 earnings report (as of September 27, 2024) highlights an increase in revenue while maintaining a high gross profit margin.

    Revenue Trends

    • Q3 2024 Revenue: $539.54 million, up from $471.92 million in Q3 2023.
    • Q2 2024 Revenue: $637.18 million, the highest in the past five quarters.
    • Q1 2024 Revenue: $425.23 million, reflecting a temporary decline from Q4 2023.

    Despite quarterly fluctuations, Exelixis has maintained a steady upward trend in revenue, driven primarily by strong sales of its flagship drug, Cabometyx, and expansion in the oncology sector.

    Profitability & Cost Management

    • Gross Profit Q3 2024: $522.21 million, up from $453.15 million in Q3 2023.
    • Gross Profit Margin: 96.8% (Q3 2024), maintaining a high profitability level.
    • Cost of Revenue: $17.33 million (Q3 2024), reflecting strong cost control.

    With a consistently high gross profit ratio (above 95%), Exelixis is efficiently managing

    This positive income statement reinforces investor confidence, making EXEL stock a compelling option for those looking for growth in the biotech sector.

    Cash Reserves

    Despite high R&D spending, Exelixis maintains a strong cash position, reducing financial risks. EXEL stock earnings report shows a positive EPS trend, reinforcing investor confidence.

    Growth Drivers and Future Potential

    Strong Drug Pipeline and R&D Expansion

    A major reason investors ask, “Is EXEL stock a good buy?” is its future growth potential. Exelixis has a promising pipeline of oncology drugs, with multiple treatments in Phase 2 and Phase 3 clinical trials.

    Partnerships and Market Expansion

    Exelixis (NASDAQ: EXEL) has been actively advancing its oncology portfolio through Phase 2 and Phase 3 clinical trials and strategic collaborations. Here are some notable examples:

    Clinical Trials

    1. STELLAR-305 Trial: Initiated in December 2023, this Phase 2/3 pivotal trial evaluates zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    2. CONTACT-02 Study: A global Phase 3 trial assessing cabozantinib combined with atezolizumab compared to a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Detailed final overall survival results were presented in September 2024.
    3. CABINET Study: This Phase 3 pivotal trial demonstrated that cabozantinib significantly improved progression-free survival in patients with advanced neuroendocrine tumors. Final results were presented at ESMO 2024 and published in the New England Journal of Medicine.

    Strategic Partnerships

    1. Merck & Co.: In October 2024, Exelixis entered a clinical development collaboration with Merck to evaluate the combination of zanzalintinib and KEYTRUDA® (pembrolizumab) in a Phase 3 trial for head and neck cancer.
    2. Catalent: Exelixis has a collaboration and license agreement with Catalent’s Redwood Bioscience subsidiary to develop multiple antibody-drug conjugates (ADCs) using Catalent’s proprietary SMARTag® technology.
    3. GlaxoSmithKline (GSK): Exelixis established a broad alliance with GSK to discover and develop novel therapeutics across various disease areas, enhancing its research capabilities and market reach.

    These clinical advancements and strategic collaborations underscore Exelixis’ commitment to expanding its oncology pipeline and enhancing its therapeutic offerings

    Stock Forecast and Growth Potential

    Industry experts believe Exelixis stock forecast remains bullish, given its consistent R&D success and upcoming drug launches.
    If Exelixis secures additional FDA approvals, the EXEL stock forecast for 2025 looks strong.

    Exelixis (NASDAQ: EXEL) has shown steady momentum in recent trading sessions, with the stock closing at $37.53 in the past two weeks. According to market predictions, EXEL stock is expected to reach $39.18 in the next two weeks, representing a potential upside. The upper predicted price target stands at $40.63, suggesting that bullish sentiment could push the stock higher if favorable catalysts, such as positive clinical trial results or strong earnings, emerge. On the downside, the lower predicted price estimate is $37.83, indicating that the stock may see limited downside risks in the near term.

    Given these projections, EXEL stock appears to be trading within a stable range, with investors watching closely for further developments in drug approvals, partnerships, and broader biotech market trends. These factors could influence whether EXEL stock breaks past its upper resistance level or trends towards its lower predicted price.

    Risks and Challenges to Consider

    Regulatory and Market Risks

    While Exelixis has seen success, investors should consider the risks of biotech investing:

    • FDA approval delays can impact stock momentum
    • Increased competition from biotech giants
    • Patent expiration concerns affecting future revenue

    Macroeconomic Impact on Biotech Stocks

    The biotech sector is highly sensitive to interest rates, healthcare policies, and regulatory changes. If market conditions shift, EXEL stock risks could become more pronounced.

    Expert & Analyst Opinions

    Wall Street Analysts on EXEL Stock

    Exelixis (NASDAQ: EXEL) has received a mix of analyst ratings, reflecting diverse market perspectives on the stock’s future trajectory. Wells Fargo’s Derek Archila recently downgraded EXEL stock from Overweight to Equal-Weight, with a price target of $36.00 as of February 24, 2025, signaling a neutral outlook.

    On the bullish side, HC Wainwright & Co.’s Robert Burns reaffirmed his Buy rating on February 13, 2025, setting a price target of $40.00, suggesting confidence in EXEL’s growth potential. Similarly, Guggenheim’s Michael Schmidt reiterated a Buy rating with a $42.00 price target, highlighting strong long-term prospects.

    Meanwhile, Barclays’ Peter Lawson maintained an Equal-Weight rating, raising his price target from $25.00 to $29.00, indicating moderate optimism. Likewise, Sudan Loganathan from Stephens & Co. reiterated an Equal-Weight rating with a $29.00 target, reflecting a cautious stance on the stock’s near-term performance.

    These mixed ratings indicate that while some analysts remain bullish on EXEL stock’s upside, others prefer a wait-and-see approach, making future earnings reports, clinical trial results, and regulatory approvals key catalysts for stock movement.

    Institutional Investor Trends

    Exelixis (NASDAQ: EXEL) enjoys significant institutional support, with approximately 89.14% of its shares held by major financial institutions. MAN GROUP PLC stands as the largest corporate investor, holding 658.86K shares valued at $15.63 million, representing a 0.22% stake in the company. Meanwhile, CITIGROUP INC owns 424.91K shares, worth approximately $10.08 million, translating to a 0.14% ownership stake.

    This high institutional ownership signals strong confidence from major financial players, as large firms typically invest in stocks with long-term growth potential. Such backing often adds stability to the stock, reducing volatility and reinforcing investor sentiment. If institutional investors continue to increase their positions, it could serve as a bullish indicator for EXEL stock in the coming months.

    Should You Buy, Hold, or Sell EXEL Stock?

    Investment Strategy for EXEL

    Given strong revenue growth, a promising drug pipeline, and positive analyst sentiment, EXEL stock presents a solid investment opportunity for long-term biotech investors. However, short-term traders should watch for FDA approvals and earnings reports before making a decision.

    • Buy for long-term growth if you believe in Exelixis’ drug pipeline.
    • Hold if you are waiting for a stronger price breakout.
    • Sell if you think competition or regulatory risks outweigh growth potential.

    Conclusion – Final Verdict on ‘Is EXEL Stock a Good Buy?’

    To answer the question, “Is EXEL stock a good buy?”—the data suggests Exelixis remains a strong contender in the biotech industry. With a solid financial base, growing product pipeline, and positive analyst outlook, the stock offers long-term growth potential.

    For biotech investors seeking stable revenue growth and innovation-driven expansion, EXEL stock may be a great buy today. However, market risks, regulatory hurdles, and competitive pressures should be carefully evaluated before making a decision.

    Final Thoughts:

    • Long-term investors: EXEL stock offers growth potential in the oncology space.
    • Short-term traders: Monitor earnings and FDA approvals before making moves.

    Would you invest in Exelixis stock? Share your thoughts in the comments!

  • How Could This Cause Exela Technologies (XELA) Stock To Rise Premarket?

    How Could This Cause Exela Technologies (XELA) Stock To Rise Premarket?

    In Tuesday’s premarket session, shares of Exela Technologies Inc. (XELA) were trading at $2.82, up 14.63%. At the close of the last trading session, Exela stock was trading at $2.46 with an increase of 1.23%. A total of 25.11 million shares of Exela Technologies were traded on Monday, below the 75.72 million shares traded on average during the last 50 days.

    Over the last one month, the XELA stock has increased 86.36%, while the shares of Exela Technologies have fallen -19.34% over the last five days. XELA stock price has risen 18.27% over the past three months and has gained 97.45 percent so far this year. XELA stock is gaining premarket following record user addition in Q2 2021.

    How did XELA add record-breaking numbers of new users?

    Exela Technologies is a provider of business process automation (BPA) solutions that improve quality, productivity, and end-user experiences. XELA has a global footprint and proprietary technology to deliver smart solutions to organizations worldwide. XELA has over 4,000 customers across 50 countries, including over 60% of the Fortune 100, and has operated mission-critical processes for decades.

    As a leading provider of information management, workflow automation, and integrated communications solutions, XELA brings innovative solutions to industries including banking, healthcare, insurance, and the public sector. XELA’s software and services are industry-specific for banking, healthcare, and insurance.

    Exela announced today that their Digital Mailroom (“DMR”) and DrySign solutions added an unprecedented number of new users during the second quarter of 2021.

    • DMR and Drysign have both grown in the preceding 90 days, with DMR growing by 99% in the SMB customer base and Drysign growing by 144% in the user base.
    • The rapid growth of XELA’s SMB solutions has been a contributing factor to all the positive feedback that it is receiving from its customers.
    • Thousand of new users are joining XELA’s customer base each month and the company is building a marketplace.
    • A new Exela Technologies product, DrySign in India, as well as DMR in the UK, were released during the second quarter as part of its plan to launch into new geographies.
    • It is planned to launch DMR in France and Germany as the next large markets in the third quarter of this year.
    • Exela Technologies continues to develop DAG offerings for SMBs and the international markets it serves.

    How has Exela Technologies grown so rapidly?

    A thriving business opportunity awaits Exela (XELA) with cross-selling, expansion, and new logos coming into fruition through multiple channels. Digital transformation is enabling XELA’s customers to enjoy many benefits as their customer base grows every month. Furthermore, Exela made use of its technology as it continued to roll out additional products for SMBs.

  • Why Did XELA Stock Plummeted Premarket?

    Why Did XELA Stock Plummeted Premarket?

    XELA Technologies Inc. (XELA) shares fell -15.50% to $2.78 in premarket trading. Last trading session, Exela stock gained 22.76% to $3.29. There were 328.21 million shares traded, which far higher than the average daily trading volume of 32.59 million shares over the last 50 days. Over the past 5-day period, XELA stock has lost 40.60%, but over the past month, it has gained 110.90%.

    This year, XELA shares have surged 146.00 percent since the start of the year. During the past three months, the stock price has risen 48.20%. XELA stock is plummeting even after reporting significant boost to cash and cash equivalents as the investors seem to be taking profits after the gain obtained in past session.

    How has XELA improved its liquidity position?

    With a global footprint and proprietary technology, Exela is one of the leading providers of business process automation (BPA) solutions that enhance quality, productivity, and end-user satisfaction. In addition to serving more than 4,000 clients throughout 50 countries, including more than 60% of the Fortune 100, XELA has decades of experience operating mission-critical processes. As a provider of end-to-end digital journey platforms, XELA releases integrated technology and operations in rapid sequence using cloud-based platforms and modules, with a worldwide workforce of more than 18,300 employees.

    It was announced today that Exela’s recently announced $150 million at-the-market equity program raised $85 million of proceeds which significantly improved liquidity position.

    • In accordance with a previously announced strategic initiative, XELA plans to use the proceeds of the equity program to reduce its debt and associated interest expenses as well as investigate ways to invest in its growth.
    • Exela intends to reduce its debt service by $25 million annually as a first step.
    • Retail investors and its shareholders at large have been the largest supporters of the XELA, while the company has been performing well recently.
    • XELA will be able to fund its growth through greater liquidity, helping it to better leverage its technology-enabled business services model.
    • Also, XELA will create significant value for equity holders by reducing its debt service by $25 million annually as it implements its strategic deleveraging.
    • XELA had over $205 million in cash and cash equivalents as of June 30, 2021.
    • As part of its credit facilities, XELA had additional borrowing capacity of $75 million available on case-by-case basis.

    XELA’s plan going forward:

    Exela (XELA) anticipates gaining access to this additional borrowing capacity in the near future, even though its $145 million A/R securitization contains $53 million available for borrowing. On its upcoming 2021 second quarter Financial Results Call, XELA will provide more information on additional steps under the strategic initiative.

  • What Is Leading The XELA Stock To Decline Premarket Session?

    Exela Technologies Inc. (XELA) is in the red today in the premarket session, falling -1.26% to $2.36 at the last check. XELA stock rose 2.14% to $2.39 on Wednesday but was down -7.95% to trade at $2.20 in afterhour trades. XELA stock volume on the day was 436.52 million, up from 8.81 million on average in the last 3 months.

    For XELA stock, the 50-day moving average is $1.65, and the 200-day moving average is $1.76. Additionally, the XELA stock is currently trading at 76.06 on the Relative Strength Index. Investors appeared to be taking profits after the XELA stock surged last session.

    Why did XELA surge in regular session?

    Exela Technologies is a business process automation (BPA) leader. XELA’s proprietary technology enables it to provide digital transformation solutions that are designed to increase quality, productivity, and end-user satisfaction. In addition to serving more than 4,000 customers throughout 50 countries, XELA has more than 60% of Fortune 100 companies as clients.

    In a statement yesterday, Exela Technologies announced that it has completed its $100 million at-the-market equity plan, which was announced on May 27, 2021.

    Additionally, XELA has established an equity investment program worth $150 million. XELA intends to use the net proceeds from the offering to repay debt, acquire or license additional product candidates, businesses, as well as raising working capital.

    Exela, in a separate statement yesterday announced that the Digital Mailroom (DMR) platform is now available for small and midsize businesses (SMBs) in the UK to sign up online.

    • More employees are choosing to work from home as the remote working trend gains wider acceptance in the operations of small businesses.
    • XELA DMR will serve this rapidly growing customer base across Europe, beginning with the UK.
    • Enterprise customers from across Europe have already access to the DMR platform through XELA.
    • A virtual office address helps small and medium businesses and startups, as well as individuals in the UK get their mail as digitized documents accessible through the DMR portal, and businesses and professionals can now register for the XELA DMR.
    • Users can choose from a variety of pricing plans and signup easily for XELA, which is a multi-industry solution.
    • The DMR service offers add-on services like parcel delivery as well as several inbuilt features such as eSignatures, data redactions and storage in addition to digitized delivery of documents.

    XELA’s disruptive approach to remote working:

    Exela (XELA)’s DMR offers an essential and valuable service for seamless business processes that goes hand-in-hand with the work from home trend. XELA’s goal with DMR is to enable businesses of any size to easily sign up and begin using its solutions since the way people and businesses work has drastically changed.

  • 21 Stocks Taking Bigger Strides in Pre Market Session

    21 Stocks Taking Bigger Strides in Pre Market Session

    ‎Velodyne Lidar Inc. (VLDR) stock soared 7.5% to $26.53 in the pre-market trading ‎after reporting that it has joined the Qualcomm® Smart Cities Accelerator Program to promote using ‎lidar technology in smart city solutions. The most recent rating by Needham, on December 15, 2020, is ‎a Buy. ‎

    ‎MicroVision Inc. (MVIS) grew over 14.38% at $6.6 in pre-market trading today.‎

    ‎Aurora Mobile Limited (NASDAQ: JG) shares are trading up 48.9% at $4.75 at the ‎time of writing following the announcement from the firm that it has entered into a partnership ‎agreement with a global leading new energy vehicle manufacturer. Company’s 52-week ranged ‎between $1.40 to $5.43.‎

    ‎Castor Maritime Inc. (CTRM) stock moved down -3.97 percent to $0.1522 in the pre-‎‎‎‎market trading.‎

    ‎HEXO Corp. (HEXO), a Drug Manufacturers – Specialty & Generic company, rose ‎about 8.0% at $1.08 in pre-market trading Tuesday after reporting lapse of base shelf prospectus.‎

    ‎Novan Inc. (NOVN) stock plunged -5.8% to $0.6396 in the pre-market trading after ‎declaring that it has entered into a Master Services Agreement (MSA) with Catalent.‎

    ‎Nano Dimension Ltd. (NNDM) gained over 2.38% at $8.61 in pre-‎‎‎market ‎trading ‎Tuesday December 22, 2020.‎

    ‎Gevo Inc. (NASDAQ: GEVO) shares are trading up 8.39% at $3.1 at the time of ‎writing following the declaration from the company that it has optioned the right to purchase ‎approximately 239 acres of land near Lake Preston, SD Company’s 52-week ranged between $0.46 to ‎‎$2.87. Gevo Options Site for Expansion Project.‎

    ‎electroCore Inc. (ECOR) gained over 7.36% at $1.75 in pre-market trading Tuesday ‎December 22, 2020 after reporting agreement with Pro Medical Baltic to be exclusive distributor for ‎gammaCore Sapphire in Eastern Europe.‎

    ‎Nxt-ID Inc. (NXTD), a Security & Protection Services company, dropped about -‎‎‎‎4.41% at $1.3 in pre-market trading Tuesday.‎

    ‎Iterum Therapeutics plc (NASDAQ: ITRM) shares are trading up 2.35% at $1.0 at the ‎time of writing after receiving approval to transfer to Nasdaq Capital Market. Company’s 52-week ‎ranged between $0.45 to $6.47. Analysts have a consensus price target of $2. ‎

    ‎Aurora Cannabis Inc. (ACB) stock moved up 2.13 percent to $9.13 in the pre-‎‎‎market ‎trading.‎

    ‎Venus Concept Inc. (VERO) tumbled over -16.14% at $2.13 in pre-market trading ‎today following the announcement of proposed public offering.‎

    ‎UP Fintech Holding Limited (NASDAQ: TIGR) shares are trading up ‎‎7.97% ‎at ‎‎$6.37 ‎at ‎the time of writing. Company’s 52-week ranged between $2.03 to $7.60.‎

    ‎IZEA Worldwide Inc. (IZEA) lost over -1.78% at $1.38 in pre-‎‎market ‎trading ‎Tuesday ‎December 22, 2020.‎

    ‎500.com Limited (WBAI), a Gambling company, rose about 9.14% at $4.18 in pre-‎market trading Tuesday following the declaration from the firm that it has entered into a definitive ‎share subscription agreement with Good Luck Information Technology Co., Limited , a company ‎incorporated in Hong Kong, for the issuance and sale of newly issued Class A ordinary shares of the ‎Company.‎

    ‎Liminal BioSciences Inc. (LMNL) stock soared 2.76% to $5.21 in the pre-‎‎‎market ‎trading. The most recent rating by Piper Sandler, on December 21, 2020, is an Overweight.‎

    ‎Palantir Technologies Inc. (PLTR) gained over 1.72% at $29.0 in pre-market trading ‎Tuesday December 22, 2020 after declaring that the U.S. Army’s Program Executive Office for ‎Enterprise Information Systems (PEO EIS) opted to execute the second year of its partnership with ‎Palantir on the Army Vantage program, for a total price of $113.8 million for the year.‎

    ‎EyeGate Pharmaceuticals Inc. (EYEG) is down more than -3.84% at $5.01 in pre-‎market hours Tuesday December 22, 2020 after announcing the acquisition of Panoptes Pharma. The ‎stock had jumped over 45.94% to $5.21 in the last trading session. ‎

    Before the trading started on December 22, 2020, Kopin Corporation (KOPN) ‎is ‎up ‎‎8.43% to reach $2.83. It has been trading in a 52-week range of $0.19 to $2.16.‎

    ‎Bit Digital Inc. (BTBT) grew over 4.96% at $6.56 in pre-market trading today following ‎the release of its third quarter of fiscal year 2020 financial results.‎

  • ‎26 stocks making the biggest moves premarket today

    ‎26 stocks making the biggest moves premarket today

    ‎Mereo BioPharma Group plc (MREO) stock plunged -7.78% to $3.32 in the pre-‎market trading after declaring collaboration and license agreement with Ultragenyx Pharmaceutical ‎Inc. (RARE), for Setrusumab in Osteogenesis Imperfecta.‎

    ‎Naked Brand Group Limited (NASDAQ: NAKD) shares are trading up ‎‎11.45% ‎at ‎‎$0.2044 at the time of writing. Company’s 52-week ranged between $0.07 to $3.70.‎

    ‎Exela Technologies Inc. (XELA) is down more than -9.79% at $0.4128 in pre-market ‎hours Monday December 21, 2020 following the announcement from the firm that it has entered into ‎a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm. The ‎stock had jumped over 26.10% to $0.46 in the last trading session.‎

    ‎Zomedica Corp. (ZOM) tumbled over -5.22% at $0.1959 in pre-market trading today.‎

    Before the trading started on December 21, 2020, BlackBerry Limited (BB) is down -‎‎3.17% to reach $6.73 after releasing financial results for the three months ended November 30, 2020. It ‎has been trading in a 52-week range of $2.70 to $9.69.‎

    ‎General Electric Company (GE), a Specialty Industrial Machinery company, dropped ‎about -6.11% at $10.15 in pre-market trading Monday after announcing expiration and results of its ‎debt tender offers.‎

    ‎Phunware Inc. (PHUN) lost over -10.38% at $0.95 in pre-‎‎market ‎trading ‎Monday ‎December 21, 2020.‎

    ‎American Airlines Group Inc. (AAL) lost over -7.03% at $15.35 in pre-market trading ‎Monday December 21, 2020.‎

    Before the trading started on December 21, 2020, Carnival Corporation & Plc (CCL) is ‎down -9.79% to reach $19.36. It has been trading in a 52-week range of $7.80 to $51.94.‎

    ‎FuelCell Energy Inc. (FCEL) stock moved down -4.3 percent to $8.9 in the pre-‎market trading after declaring that state regulators have improperly rescinded RFP awards for three ‎fuel cell projects previously selected in the Shared Clean Energy Facility program, putting its state high ‎tech manufacturing job growth at risk.‎

    ‎Exicure Inc. (XCUR) stock soared 7.04% to $2.13 in the pre-‎‎market ‎trading. ‎The ‎most ‎recent rating by BMO Capital Markets, on December 18, 2020, is ‎an ‎Outperform.‎

    ‎Genius Brands International Inc. (GNUS), a Entertainment company, rose about ‎‎3.18% at $1.62 in pre-market trading Monday. The firm recently revealed that it has licensed streaming ‎and select video-on-demand rights to the hit family series, The Wubbulous World of Dr. Seuss (20 x ‎‎22’), from The Jim Henson Company on Kartoon Channel!‎

    ‎SolarWinds Corporation (NYSE: SWI) shares are trading ‎up ‎‎6.7% ‎at ‎‎$15.13 ‎at ‎the ‎time of writing. Company’s 52-week ranged between $11.50 ‎to ‎‎$24.34. ‎Analysts ‎have ‎a ‎consensus ‎price target of $26. ‎

    ‎Norwegian Cruise Line Holdings Ltd. (NCLH) lost over -10.01% at $22.66 in pre-‎market trading Monday December 21, 2020 after reporting that it has closed its previously announced ‎private offering of $850 million aggregate principal amount of its 5.875% senior notes due 2026 (the ‎‎“Notes”).‎

    Before the trading started on December 21, 2020, Nokia Corporation (NOK) is down ‎‎-5.25% to reach $3.79. The company recently declared that it has launched 5G services with Polkomtel, ‎operator of the Plus network, in the capital city of Warsaw as well as other major cities in the eastern ‎part of the country. It has been trading in a 52-week range of $2.34 to $5.14.‎

    ‎Corbus Pharmaceuticals Holdings Inc. (CRBP) is up more than 12.0% at $1.68 in pre-‎‎‎‎‎‎‎‎market hours Monday December 21, 2020. The stock had jumped ‎over ‎‎11.11% ‎to ‎‎$1.50 ‎in ‎the ‎last ‎trading session.‎

    ‎Schlumberger Limited (NYSE: SLB) shares are trading down -6.95% at $20.76 at the ‎time of writing. The firm will hold a conference call on January 22, 2021 to discuss the results for the ‎fourth quarter and full year ending December 31, 2020. Company’s 52-week ranged between $11.87 to ‎‎$41.14.‎

    ‎Exxon Mobil Corporation (NYSE: XOM) shares are trading down -5.27% ‎at ‎‎$40.48 ‎at ‎the time of writing. Company’s 52-week ranged between $30.11 to $71.37. Analysts ‎have ‎a ‎consensus ‎price target of $52.‎

    ‎Transocean Ltd. (RIG) is down more than -14.92% at $2.11 in pre-market hours ‎Monday December 21, 2020 after announcing successful court ruling granting its motion for summary ‎judgment and holding internal reorganization did not violate indenture. The stock had dropped over -‎‎3.50% to $2.48 in the last trading session.‎

    ‎Simon Property Group Inc. (SPG) tumbled over -5.07% at $81.1 in pre-market ‎trading today. The firm recently declared a common stock dividend for the fourth quarter 2020.‎
    ‎
    ‎Energy Transfer LP (ET), a Oil & Gas Midstream company, dropped about -‎‎‎‎5.9% ‎at ‎‎$6.38 in pre-market trading Monday.‎

    ‎Cinedigm Corp. (CIDM) stock moved up 4.11 percent to $0.798 in the pre-market ‎trading after revealing the launch of The Bob Ross Channel on the Roku platform.‎

    Before the trading started on December 21, 2020, Coty Inc. (COTY) is down -6.15% ‎to reach $6.56. The company lately reported two additions to its Board of Directors with the ‎appointments of Anna Adeola Makanju and Mariasun Aramburuzabala Larregui. It has been trading in ‎a 52-week range of $2.65 to $13.01.‎

    ‎JPMorgan Chase & Co. (JPM) gained over 2.24% at $121.75 in pre-‎‎‎‎market ‎trading ‎Monday December 21, 2020. ‎

    ‎Apache Corporation (NASDAQ: APA) shares are trading down -11.29% at $13.6 at ‎the time of writing after announcing the donation of more than 64,000 trees to 56 nonprofit partner ‎organizations through the annual Apache Tree Grant Program. Company’s 52-week ranged between ‎‎$3.80 to $33.77. Analysts have a consensus price target of $16.‎

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.